To improve the therapeutic efficacy and cancer-specific delivery of MDA-7/IL-24, Sarkar et al. created a bipartite CRCA expressing mda-7/IL-24 [10,83,84,96], in which E1A and E1B (replication component) expression is regulated by a cancer-selective minimal active region of the promoter of progression elevated gene-3 (PEG-3), which functions selectively in diverse cancer cells with limited activity in normal cells [97,98]. Here, DHTKD1 is linked to cancer.